Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.00 - $177.37
Previous CloseN/A
Volume1.17M
Average Volume (3M)1.25M
Market Cap
$2.32B
Enterprise Value$5.79B
Total Cash (Recent Filing)$336.65M
Total Debt (Recent Filing)$458.92M
Price to Earnings (P/E)68.4
Beta1.70
Next Earnings
May 06, 2025EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.01
Shares Outstanding33,662,360
10 Day Avg. Volume884,990
30 Day Avg. Volume1,251,535
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.26
Price to Cash Flow (P/CF)29.60
P/FCF Ratio29.60
Enterprise Value/Market Cap2.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.09
Enterprise Value/Ebitda91.61
Forecast
1Y Price Target
$100.71Price Target Upside45.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
TransMedics Group News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTransmedics Group reported revenue and earnings per share that exceeded estimates, showcasing strong performance and boosting confidence in the company's stock.
Market Share And GrowthTransmedics Group's expectation to capture revenue from clinical trial patients using the OCS system presents potential upside for future financial estimates.
Revenue GrowthThe company's guidance for 2025 indicates a significant revenue growth rate of 20%-25%, suggesting strong future prospects.
Bears Say
CompetitionThere are concerns about increasing competition affecting TMDX.
Competitive EnvironmentInvestor sentiment will likely remain mixed as the 2025 outlook calls for a deceleration in growth and as investors continue to debate the competitive environment.
Market PositionThe overhang from Scorpion raises concerns about TMDX's market position.
---
Ownership Overview
3.59% Insiders
36.87% Mutual Funds
24.84% Other Institutional Investors
9.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $55.00 and its highest was $177.37 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $2.32B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is May 06, 2025 which is in 42 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Feb 27, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.03.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.26.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 33,662,360 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.19 in its last earnings report, beating expectations of $0.16. Following the earnings report the stock price went up 5.824%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
---
TransMedics Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$100.71 (45.85% Upside)
$100.71 (45.85% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 94%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 749.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $184.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.66%
12-Months-Change
Fundamentals
Return on Equity
19.39%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc. is a medical technology company that specializes in organ transplant solutions. The company is known for developing the Organ Care System (OCS), a proprietary technology platform designed to optimize the preservation, assessment, and transport of donor organs intended for transplantation. TransMedics' innovative products aim to improve organ utilization and transplant outcomes across multiple organ types, including heart, lung, and liver, thus addressing critical challenges in the organ transplantation industry.
---
TMDX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
TransMedics' earnings call reflects strong financial performance and market share gains, particularly in the U.S., with significant revenue growth and operational improvements. However, there are challenges in gross margin, international revenue, and potential operational hurdles. The company has addressed recent allegations but faces variability in logistics and clinical program timelines.Read More>---
TMDX Stock 12 Month Forecast
Average Price Target
$100.71
▲(45.85% Upside)
Technical Analysis
Best Analysts Covering TMDX
1 Year
1 Year Success Rate
15/24 ratings generated profit
1 Year Average Return
+41.34%
reiterated a buy rating 16 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +41.34% per trade.
---